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Many studies have reported the growing prevalence of human 
papillomavirus (HPV) in head and neck squamous cell cancers. Chaturvedi 
et al. observed significantly increased oropharyngeal cancer incidence 
during 1983 to 2002 predominantly in developed countries and at younger 
ages; results that underscore a potential role of HPV infection on increasing 
OPC incidence, particularly among men. Male predominance could be 
explained by the fact that during active orogenital encounter (assuming 
heterosexual relationship) males are exposed to a greater HPV load since 
the infected cervical secretes contain far more HPV virus particles than the 
infected penis. 
Data of large studies show that HPV-positivity rate of oropharyngeal 
cancers was 24.3% assessed by HPV DNA and p16INK4 dual testing. 
Nevertheless, there was still a lack of consensus concerning the use 
diagnostic methods needed to detect HPV association. In this study, we 
assessed the predictive role p16INK4-expression versus p16INK4/HPV PCR 
double testing in Hungarian oropharyngeal cancer patients with regard to 
response to induction chemotherapy. 
Immunotherapy has evolved greatly during the last decade and holds the 
promise of a revolution in the treatment of cancer. There is great enthusiasm 
towards immunotherapeutic approaches of HNSCC, since it is a disease 
characterized by profound involvement of the immune system. Checkpoint 
inhibitors such as anti-PD-1 monoclonal antibody nivolumab and 
pembrolizumab has recently gained FDA approval for the treatment of 
recurrent or metastatic HNSCC. Despite intense research, there is still an 
urging need for prognostic and predictive biomarkers. Besides tumor cell 
markers, the attention is now focused on markers of immune activation as 
well.  
In this study we investigated the possibly existing differences between 
subsets of HNSCC based on clinicopathological data and correlations 
between immunoncological markers. Here, the term subset referred to 
subgroups according to HPV status and anatomical localization. The 
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rationale of this approach on one hand was the growing body of evidence 
that suggests differences in the expression of multiple biomarkers. On the 
other hand, it became clear in recent years, that HPV associated and non-
HPV associated HNSCCs are distinct biologic entities. 
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2. Objectives
Our first question was weather HPV status is a predictive factor as well. In 
order to answer this question we compared the response rate of p16INK4/
HPV-positive versus p16INK4/HPV-negative oropharyngeal cancer patients 
that were treated with induction chemotherapy. 
Our second objective was to investigate the expression of checkpoint 
inhibitor proteins in HNSCC.  
Finally, we also wanted to find out weather checkpoint inhibitor protein 
expression is related to subsets of head and neck cancer, such as anatomical 
localization or subgroups based on p16INK4/HPV status. Thus, we assessed 
expression of PD-1, PD-L1, PD-L2 and CTLA-4, just as markers of 
immune activation: CD8-expression and the rate of tumor infiltrating 




We enrolled 124 therapy naive, consecutively diagnosed individuals with 
squamous cell carcinoma of the head and neck. We excluded tumors of 
nasopharyngeal or paranasal sinus localization. Out of this, 110 patients had 
available tumor blocks for immunohistochemical staining. For the research 
of immune checkpoint inhibitors we excluded oral cavity cancer patients 
(N=3) to increase homogeneity and one other patient whose archival tumor 
block was consumed by previous research, thus did not met the inclusion 
criteria any more. Doing so we left 106 individuals in the analysis. Each 
patient underwent treatment between 2012 and 2014 at the Department of 
Oto-Rhino-Laryngology, Head and Neck Surgery, Semmelweis University 
(Budapest, Hungary). This research was approved by the Regional, 
Institutional Scientific and Research Ethics Committee of Semmelweis 
University (SE TUKEB 105/2014). 
Study design
Predictive value of p16INK4 and HPV DNA PCR status 
First, p16INK4 immunohistochemical staining was performed on each tumor 
sample. Those tested positive for p16INK4 underwent subsequent real-time 
high-risk HPV DNA PCR analysis. P16INK4 and HPV DNA PCR double 
positive samples were regarded as HPV positive. We selected patients who 
had an oropharyngeal tumor and received induction chemotherapy. 
Therapeutic response was assessed based on Response Evaluation Criteria 
in Solid Tumors (RECIST) 1.1. We sought association between p16INK4/
HPV status and therapeutic response (complete remission/partial remission/
stable disease or progressive disease). 
Expression of immune checkpoint inhibitors in subsets of HNSCC 
We retrieved clinical parameters (localization, stage, grade, gender, smoking 
habits, alcohol consumption, response to induction chemotherapy, response 
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to chemoradiotherapy) from our clinical database and utilized information 
on p16INK4/HPV status gained from the previous analysis.  
The expression of PD-1 on immune cells and the expression of PD-L1 and 
CTLA-4  on both tumor and immune cells were observed. We evaluated 
PD-L2 expression on tumor cells only. The rate of CD8+ mononuclear cells 
and the proportion of tumor infiltrating lymphocytes (TILs) was assessed as 
well. We primarily aimed to investigate the prognostic impact of PD-1, PD-
L1, PD-L2 and CTLA-4 expression as well as TIL density in HNSCC. In 
particular we focused on differences between subsets of this disease. 
Subsets were defined either as subgroups  according to anatomical 
localization or subgroups based on p16INK4/HPV status. 
Tissue microarray construction
Formalin-fixed, paraffin-embedded (FFPE) tissue block were retrieved from 
archives  of the 2nd Department of Pathology, Semmelweis University. 
Consequently, all blocks were created using uniform methods based on the 
local institutional protocol. TMA blocks containing 2 mm diameter cores 
were created using the TMA Master instrument (3DHISTECH Kft, 
Budapest, Hungary). TMA blocks contained 50 or 70 cores each. To avoid 
misrepresentation of samples, 2-3 cores were acquired per tumor. Tissue 
sections (4 micrometer) were cut on adhesion slides and used for 
immunohistochemical analysis. Similar sections were cut for DNA 
extraction and real-time PCR testing. 
Immunohistochemistry and evaluation of slides
Immunohistochemistry was performed at the 2nd Department of Pathology, 
Semmelweis University. After immunostaining, slides were digitalized 
using a Pannoramic Scan instrument (3DHISTECH, Hungary). Three 
independent observers blinded to clinical data performed scoring of 
immunoreactions employing the Pannoramic Viewer software 
(3DHISTECH, Hungary). In case of inter-observer differences reevaluation 
took place by all 3 participants and a consensus was reached. 
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p16INK4 staining 
BenchMark XT IHC/ISH (Roche, Germany) semi-automated device was 
used for p16INK4 staining with the application of XT UltraView DAB v3 kit. 
The protocol of staining method was carried out. Briefly, sections were 
incubated at 72 °C for 4 min. We used EZ Prep Solution (Ventana Medical 
Systems, Tucson, AZ, USA) three times to remove paraffin. Cell 
conditioning solution pH 8 (Ventana Medical Systems) was used for heat 
induced epitope retrieval at 95 °C for 30 min followed by a heating at 100 
°C for 4 min. Endogenous peroxidase activity was inhibited with one drop 
UV INHIBITOR (Ventana), which was applied at 37 °C for 6 min. Primary 
monoclonal antibody against p16INK4 (Clone CINtec E6H4, Ventana) was 
applied at 37 °C for 32 min in a dilution of 1:100. After incubation with UV 
HRP UNIV MULT secondary antibody solution (Ventana) at 37 °C for 8 
min, peroxidase activity was visualized with diaminobenzidine (DAB) 
chromogen (Ventana). Nuclear counter-staining was done with hematoxylin 
II (Ventana). All washing steps were performed with diluted Reaction 
Buffer Concentrate (Ventana). In each core, nests of at least 200 tumor cells 
were analyzed by two independent assessors. Cut-off for p16INK4-
immunolabelling was set at 75% of cytoplasmic or nuclear staining. 
Intensity of staining played no role in the evaluation. However, almost all 
p16INK4-positive samples showed a remarkably strong intensity. 
PD-L1 staining 
Immunohistochemical staining of PD-L1, PD-1, PD-L2, CTLA-4 and CD-8 
was performed similarly. Briefly, all slides were deparaffinized and 
immunostained with primary antibodies at 42°C for 32 minutes following 
antigen retrieval. PD-L1 labeling alone required 10 minutes longer antigen 
retrieval and for PD-L1 the primary antibody  incubation time was 2 hours. 
Detection was performed using a secondary antibody for 60 min at room 
temperature following the protocols of ultraView™ Universal DAB 
Detection Kit (Ventana Benchmark Ultra, Ventana Medical Systems Inc., 
Tucson, Arizona, USA). Positive controls were included in each run 
showing appropriate results. Slides were counterstained with hematoxylin, 
washed in water, dehydrated, and cover-slipped before analysis. After initial 
manual calibration of the optimal dose of the primary antibody, an 
automatic immunostainer (Ventana Benchmark Ultra, Ventana Medical 
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Systems Inc., Tucson, Arizona, USA) was used for the serial 
immunolabeling.  
PD-L1 score categories on tumor cells (PD-L1TC) were formed based on the 
most relevant cut-off values of PD-L1 staining. PD-L1TC categories were: 0: 
no staining, 1: 0-1%, 2: 1-5%, 3: 6-10%, 4: 11-25%, 5: 26-100%. Scores 
greater than 1 were considered positive.   
PD-L1 staining on immune cells (PD-L1IC) was evaluated  as follows: 0: no 
staining, 1: <1%, 2: 1-5%, 3: >5%. Staining scores higher than 0 were 
regarded positive. 
PD-L2 staining 
PD-L2, PD-1, CTLA-4 and CD-8 staining was performed as described 
above. 
PD-L2 immunoscore was allotted to specimens as described elsewhere. The 
stained tumor cells percentage scores (0: no staining, 1: <10%, 2: 10-50%, 
3: >50%) and intensity scores (0: no staining, 1: week, 2: moderate, 3: 
strong) were summed. The summed score was regarded negative when 0-4 
and positive when it was 5 or 6.  
PD-1 staining 
PD-1 staining on immune cells was assessed: 0: <1%, 1: 1-5%, 2: >5%. 
Scores 1 and 2 considered to be positive. 
CTLA-4 staining 
CTLA-4 immunolabeling was investigated on both tumor cells (CTLA-4TC) 
and immune cells (CTLA-4IC). Given the scarcity of studies describing 
CTLA-4 expression on tumor cells, we decided to evaluate the samples per 
10%; 0: no staining, 1: 1-10%, 2: 11-20%, etc. Positivity was defined when 
the score exceeded the median value as previously described. The median 
score of CTLA-4TC was 0 and >1% staining was regarded as positive. The 
same method was implemented in the assessment of CTLA-4IC staining 
with >40% immune cell staining regarded as positive. 
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CD-8 staining 
CD8 staining was evaluated as previously described: 0: <1%, 1: 1-5%, 2: 
6-20%, 3: >20% High expression was declared if staining of lymphocytes 
was >20%. 
High-risk HPV DNA real-time polymerase chain reaction
Human DNA was extracted from FFPE tissue sections in cases showing 
p16INK4-immunolabelling by QIAmp DNA FFPE Tissue Kit (Qiagen, 
Hilden, Germany) in line with the manufacturer’s instructions. High-risk 
HPV DNA detection was performed using CONFIDENCE™ HPV test 
(NEUMANN Diagnostics, Hungary) combined with genotyping for HPV 
16, 18, 31, 33, 45, 52, 58. The sufficient amount of input DNA was 
controlled by fluorometric quantitation by Qubit™ Fluorometer (Invitrogen, 
Carlsbad, CA, USA) using Qubit™ dsDNA HS Assay Kit (Invitrogen) 
according to the manufacturer’s protocol. 
CONFIDENCE™ HPV is a TaqMan®-based L1 region specific multiplex 
real-time PCR assay for viral DNA detection. The test detects HPV 16 and 
18 separately and other high-risk types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59, 66, 68) in a pooled manner. In case of high-risk HPV presence, 
genotyping was performed using type specific primers in separated 
reactions. The quantitative real-time PCR was carried out on QuantStudio™ 
6 Flex platform (Thermo Fisher Scientific, Waltham, MA, USA) in 384-
well plate format. 
Tumor infiltrating lymphocyte (TIL) ratio
The proportion of TIL was assessed on hematoxylin and eosin (HE) stained 
whole tumor slides by an experienced pathologist (JH). Briefly, TIL scoring 
was based on the area occupied by mononuclear cells relative to the entire 
stromal area. Scores were distributed as follows: low: 0-33%, moderate: 
34-66%, high: 67-100%. 
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Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics for Mac 
version 20.0.0 (SPSS Inc., Chicago, IL, USA). Pearson Chi-square tests and 
Fisher exact tests were used to test correlations between discrete variables. 
In case of survival analysis, Kaplan-Meier estimation with Log Rank test as 
well as univariate and multivariate regression were applied. All tests were 2-
sided and p-values <0.05 were considered statistically significant. The 
following variables were used in the analysis: gender, tumor localization, 
HPV status, TNM stage, grade, response to induction chemotherapy, 
response to chemoradiotherapy, tobacco consumption, alcohol consumption 
and the biomarkers listed above. Disease-specific survival (DSS) time was 




P16INK4-expression and high risk HPV DNA status
The result of p16INK4 immunohistochemistry was available in 110 patients. 
Out of the 110 tumor samples, 19 cases (17.3%) proved to be p16INK4-
positive. The highest proportion of p16INK4-positive cases was observed in 
oropharyngeal tumors (38.1%), whereas other locations showed much lower 
(larynx: 4.8%, hypopharynx: 4.2%) or no (oral cavity: 0%) p16INK4-
immunolabelling rate. 
Out of 19 cases, 9 tumors harboured HPV DNA (HPV-positive cases). HPV 
16 was present in 8 cases, HPV 33 in one single case. All HPV-positive 
samples originated from the oropharynx. This means that the rate of HPV-
associated oropharyngeal cancers was 21.4% (9/42 patients). Thus, the 
specificity of p16INK4 to detect oropharyngeal HPV presence was 56.3% 
(out of the 16 p16INK4-positive oropharyngeal tumors, 9 cases tested positive 
for HPV as well). 
P16INK4/HPV DNA status and response to induction chemotherapy
Of the 110 patients with available immunohistochemical staining, 32 
patients received induction chemotherapy. TPF (docetaxel plus cisplatin 
plus 5-fluorouracil) was given in 30 cases and for 2 patients PF (cisplatin 
plus 5-fluorouracil) was the choice. P16INK4-positive individuals showed a 
better response compared with the p16INK4-negative group (Fisher’s exact 
test: p = 0.025). There was a significant difference between groups based on 
HPV status as well (Fisher’s exact test: p = 0.009). 
The impact of TIL rate
Our samples showed a high infiltration rate by TILs. A low TIL score was 
observed in 27.3% of cases whereas moderate and high infiltration was seen 
in 21.2% and 51.5%, respectively. Interestingly, PD-L1IC positivity was 
associated with high TIL rate in the whole patient sample (Chi-square: 
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p=0.016) and when observed in anatomical subsets separately in the 
hypopharynx only (Fisher’s exact test p=0.006). TIL score correlated 
positively with CTLA-4IC expression (Chi-square: p=0.013). Observing 
anatomical subgroups separately, TIL score and CTLA-4IC expression 
correlated in the hypopharynx only (Fisher’s exact test: p=0.028). In 
oropharyngeal tumors, TIL score was not associated with HPV status 
(Fisher’s exact test: 0.474). We could not find differences in survival nor 
could we establish association with any other parameters and TIL score. 
CD8 expression
High CD8 expression was associated with the presence of PD-L1 on tumor 
cells (Chi-square: 0.001) and PD-L1IC positivity showed a positive 
correlation with CD8 status (Chi-square: 0.023) as well. Interestingly none 
of the samples lacked entirely CD8+ T cell infiltration.  
PD-L1 expression on immune cells (PD-L1IC)
Considering HPV-negative tumors of all localizations PD-L1IC positivity 
was proved to be associated with better DSS (HR=0.502; CI95%, 
0.273-0.923; p=0.027). In laryngeal tumors, PD-L1IC positivity was 
associated with improved DSS (HR=0.222; CI95%, 0.062-0.795; p=0.021) 
compared to the PD-L1IC negative group. In the multivariate analysis 
controlling for gender, tumor localization and stage, PD-L1IC status did not 
prove to be an independent prognostic factor. Furthermore, PD-L1IC 
positivity showed a positive correlation with CTLA-4IC positivity (Chi-
square: p=0.049. TIL score correlated positively with PD-L1IC expression as 
stated above. 
PD-L1 expression on tumor cells (PD-L1TC) was not associated with 
disease-specific survival
PD-L1TC and PD-1 status showed a remarkably strong positive correlation 
in all patients (Chi-square: p<0.001) and in oropharyngeal and laryngeal 
localization (Fisher’s exact test for oropharynx: p<0.001; larynx: p=0.006), 
whereas in the hypopharynx the level of significance was not reached 
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(Fisher’s exact test: p=0.074).  Negative HPV status was associated with 
negative PD-L1TC expression in case of oropharyngeal malignancies 
(Fisher’s exact test: p=0.019). 
PD-1 expression
Besides the above mentioned data, PD-1 status did not correlate with 
anatomical subsets (Chi-square: 0.239), HPV status (Chi-square: p=0.601) 
or with any other parameters observed. 
PD-L2 expression
Observing only HPV-negative tumors PD-L2 expression negatively 
correlated with the presence of PD-1 (Chi-square: p=0.027). None of other 
biomarkers or clinicopathological parameters were associated with PD-L2 
status. 
CTLA-4  expression on immune cells (CTLA-4IC) and tumor cells 
(CTLA-4TC)
TIL score correlated positively with CTLA-4IC expression as described 
above. As mentioned earlier, CTLA-4IC expression correlated with PD-L1IC 
positivity. We have found that a proportion of HNSCC tumor cells showed 
faint cytoplasmic positivity for CTLA-4. None of the biomarkers or 
clinicopathological parameters were associated with CTLA-4TC  expression. 
Anatomical localization and survival
Laryngeal cancer was characterized by superior DSS when compared to 
tumors of pharyngeal origin (HR=0.306; CI95%, 0.152-0.616; p=0.001; 
Log Rank p<0.001). However, this relation became tendential only when 
observation was limited to patients with locoregionally advanced (stage III-
IV B) disease (Log Rank p=0.057). 
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5. Conclusions
The predictive role of p16INK4 immonuhistochemistry versus p16INK4/
PCR double testing regarding  induction  chemotherapy  in 
oropharyngeal squamous cell carcinoma:
1. P16INK4 immunohistochemistry can be considered a possible, 
precise and widely affordable tool in predictive characterization of 
oropharyngeal squamous cell cancers in term of response to 
induction chemotherapy.  
2. In comparison with p16INK4/HPV DNA PCR double testing, 
p16INK4 status alone proved to be an equivocally precise indicator 
of clinical outcome. 
Expression of checkpoint inhibitor proteins in subsets of head and neck 
cancer 
3. Our results showed a survival benefit of PD-L1 expression on 
immune cells in HPV-negative HNSCC. 
4. PD-L1IC expression was found to indicate a better prognosis in 
laryngeal squamous cell carcinoma as well. 
5. PD-L2 expression showed no correlation with any parameters 
observed, except for a negative correlation with PD-1-positive 
status. 
6. We found a proportion of HNSCC expressing CTLA-4 in tumor 
cell but failed to prove any clinical significance or correlation with 
other markers. 
7. We have not found any remarkable differences between 
anatomical subgroups of HNSCC. 
8. HPV status clearly divided subsets of this disease in terms of 
cancer immunity. 
9. A possibly distinct role of hypopharyngeal localization with regard 
to immune activity requires further clarification by larger studies. 
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